Fluphenazine/nortriptyline in the irritable bladder syndrome. A double-blind placebo controlled study.
A double-blind, placebo controlled, randomised order crossover study was carried out on the effect of Motival (0.5 mg fluphenazine with 10 mg nortriptyline) 3 times daily on the bladder function and psychiatric morbidity of 13 women without evidence of infection, complaining of recurrent dysuria and frequency. Bladder function was assessed symptomatically and by ambulatory urodynamics, and patients completed the General Health Questionnaire, a validated instrument for the detection of psychiatric disturbance. Correction of the urodynamic abnormalities was associated with Motival treatment in 5 of the 8 patients with unstable bladders, compared with none of 7 patients receiving placebo (P less than 0.02). Motival was also associated with a greater frequency of symptomatic improvement. Only 2 patients were classified as psychiatrically disturbed, suggesting that the therapeutic effect of Motival is not related to its psychotropic properties.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009661:Nortriptyline / Q000627:therapeutic use*; D013577:Syndrome; D001743:Urinary Bladder / Q000503:physiopathology; D001745:Urinary Bladder Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D014563:Urodynamics
D004338:Drug Combinations; C028045:Motival; D009661:Nortriptyline; D005476:Fluphenazine